Get started
Author

Maria Laura Annunziata

Observed names: M L Annunziata, M. Annunziata, M. L. Annunziata, M.L. Annunziata, Maria Annunziata, Maria L Annunziata, Maria L. Annunziata
Observed institutions: Università Cattolica del Sacro Cuore, Vita-Salute San Raffaele University, Università Campus Bio-Medico, University of Chicago, University of Chicago Medical Center, Azienda Ospedaliera San Camillo-Forlanini, IRCCS Policlinico San Donato, Campus Bio Medico University Hospital
ORCID: 0009-0008-5069-5513
Observed ORCID: 0009-0008-5069-5513
OpenAlex ID: A5023617515
Intestinal epithelial vitamin D receptor signaling inhibits experimental colitis
2013 · Weicheng Liu, Yunzi Chen, et al. · Journal of Clinical Investigation · 343
PDF
Upper Gastrointestinal Involvement of Crohn’s Disease: A Prospective Study on the Role of Upper Endoscopy in the Diagnostic Work-Up
2012 · Maria Laura Annunziata, Renato Caviglia, et al. · Digestive Diseases and Sciences · 150
Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study
2024 · Marc Ferrante, Geert D'Haens, et al. · The Lancet · 148
PDF
The PROSIT-BIO Cohort: A Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Infliximab Biosimilar
2017 · Gionata Fiorino, Natalia Manetti, et al. · Inflammatory Bowel Diseases · 133
Development and Validation of an Endoscopic Classification of Diverticular Disease of the Colon: The DICA Classification
2014 · Antonio Tursi, Giovanni Brandimarte, et al. · Digestive Diseases · 91
Role of spiramycin/cotrimoxazole association in the mother-to-child transmission of toxoplasmosis infection in pregnancy
2008 · P. Valentini, M. L. Annunziata, et al. · European Journal of Clinical Microbiology & Infectious Diseases · 87
The PROSIT Cohort of Infliximab Biosimilar in IBD: A Prolonged Follow-up on the Effectiveness and Safety Across Italy
2018 · Alessandro Armuzzi, Gionata Fiorino, et al. · Inflammatory Bowel Diseases · 59
PDF
Predictive value of the Diverticular Inflammation and Complication Assessment (DICA) endoscopic classification on the outcome of diverticular disease of the colon: An international study
2015 · Antonio Tursi, Giovanni Brandimarte, et al. · United European Gastroenterology Journal · 56
Prognostic performance of the ‘DICA’ endoscopic classification and the ‘CODA’ score in predicting clinical outcomes of diverticular disease: an international, multicentre, prospective cohort study
2021 · Antonio Tursi, Giovanni Brandimarte, et al. · Gut · 37
Mucosal Healing Is Associated with Improved Long-term Outcome of Maintenance Therapy with Natalizumab in Crohnʼs Disease
2013 · Atsushi Sakuraba, Maria L. Annunziata, et al. · Inflammatory Bowel Diseases · 28
Prevalence and Natural History of Segmental Colitis Associated With Diverticulosis
2023 · Antonio Tursi, Daniele Piovani, et al. · The American Journal of Gastroenterology · 17
Diverticular Inflammation and Complication Assessment classification, CODA score and fecal calprotectin in clinical assessment of patients with diverticular disease: A decision curve analysis
2023 · Antonio Tursi, Daniele Piovani, et al. · United European Gastroenterology Journal · 13
PDF
Management of inflammatory bowel disease: past, present and future
2012 · Kian Keyashian, Maria Laura Annunziata, et al. · Expert Review of Clinical Immunology · 13
Efficacy and tolerability of high and low-volume bowel preparation compared: A real-life single-blinded large-population study
2021 · Vincenzo Occhipinti, Paola Soriani, et al. · World Journal of Gastrointestinal Endoscopy · 11
PDF
Risk factors for inadequate bowel preparation in patients using high- and low-volume cleansing products
2022 · Vincenzo Occhipinti, Paola Soriani, et al. · European Journal of Gastroenterology & Hepatology · 8
439 The PROSIT-BIO Cohort of the IG-IBD: A Prospective Observational Study of Patients With Inflammatory Bowel Disease Treated With Infliximab BioSimilars
2016 · Gionata Fiorino, Natalia Manetti, et al. · Gastroenterology · 6
P402 Normalized wall thickness at MRE predicts clinical remission in Crohn's disease after infliximab discontinuation: a 5 years follow-up
2014 · M.L. Annunziata, L.G. Papparella, et al. · Journal of Crohn s and Colitis · 5
P.02.12 Predictive Value of the “dica” Endoscopic Classification on the Outcome of Diverticular Disease of the Colon: a 1-year Analysis From the International, Multicenter, Prospective Study
2019 · A. Tursi, G. Brandimarte, et al. · Digestive and Liver Disease · 4
CHRONIC IDIOPATHIC THROMBOCYTOPENIC PURPURA IN CHILDREN: Case Reports of Spontaneous Recovery Without Splenectomy
2006 · A. Ruggiero, M. L. Annunziata, et al. · Pediatric Hematology and Oncology · 4
Efficacy of vedolizumab as maintenance therapy in a patient with ulcerative colitis receiving haemodialysis in end-stage kidney failure: A case report
2023 · Guglielmo Albertini Petroni, Laura Francesca Pisani, et al. · SAGE Open Medical Case Reports · 3
Esophageal post-inflammatory polyposis in extensive and severe Crohn’s disease treated with anti-tumor necrosis factor alpha
2016 · Paola Soriani, Gian Tontini, et al. · Endoscopy · 3
PDF
Calcineurin inhibition in severe ulcerative colitis: Lost in translation?
2011 · Maria Laura Annunziata, Stephen B. Hanauer · Inflammatory Bowel Diseases · 3
P139 A potential protective rule of Mannose Binding lectin (MBL) against SARS-COV2 infection in IBD patients
2024 · G Albertini, L F Pisani, et al. · Journal of Crohn s and Colitis · 2
PDF
DOP36 Vedolizumab-treated IBD patients show an increased gut microbial diversity associated with a specific serum metabolic signature
2023 · L F Pisani, G Crespi, et al. · Journal of Crohn s and Colitis · 2
PDF
A Prolonged Follow-Up on the Efficacy and Safety of Infliximab Biosimilar CT-P13 in IBD Across Italy: The Prosit Cohort
2017 · Alessandro Armuzzi, Gionata Fiorino, et al. · Gastroenterology · 2
Works count: 67
Citation count: 1,237
H-index: 13
I10-index: 14
Year
Topic
Type